| Alison M. Goate | |
|---|---|
| Photo placeholder | |
| Affiliations | Icahn School of Medicine at Mount Sinai |
| Country | USA |
| H-index | 150 |
| ORCID | 0000-0002-4517-9432 |
| Research Focus | Alzheimer's Disease, FTD |
| Mechanisms | Genetics, APP, Risk genes |
Alison M. Goate is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Alison M. Goate is a leading researcher in the field of neurodegenerative diseases, affiliated with Icahn School of Medicine at Mount Sinai. Their research focuses on the genetics of Alzheimer's Disease and Frontotemporal Dementia, with particular emphasis on identifying genetic risk factors and understanding disease mechanisms.[1]
Goate's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and FTD. Their research group has made significant contributions to the field of Alzheimer's Disease genetics, publishing in high-impact journals including Nature, Nature Genetics, and the New England Journal of Medicine.[2]
Based at Icahn School of Medicine at Mount Sinai, Goate collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Goate has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at Icahn School of Medicine at Mount Sinai, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.[3]
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.[4]
Representative output includes foundational work on [APP[/entities/[app-protein[/entities/[app-protein[/entities/[app-protein--TEMP--/entities)--FIX-- mutations in familial Alzheimer's Disease (1991), published in Nature, which established the amyloid cascade hypothesis.[1]
Their program contributes to translational and mechanistic work in Alzheimer's Disease. Their program contributes to translational and mechanistic work in FTD.
The lab emphasizes genetics to connect molecular findings with patient outcomes. The lab emphasizes APP to connect molecular findings with patient outcomes. The lab emphasizes risk genes to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.[5]
Current priorities in Goate's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response.[6] A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.[7]
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.[8]
[John Q. Trojanowski[/researchers/[john-trojanowski[/researchers/[john-trojanowski[/researchers/[john-trojanowski--TEMP--/researchers)--FIX--, [Bin Zhang[/researchers/[bin-zhang[/researchers/[bin-zhang[/researchers/[bin-zhang--TEMP--/researchers)--FIX--, [Eric E. Schadt[/researchers/[eric-schadt[/researchers/[eric-schadt[/researchers/[eric-schadt--TEMP--/researchers)--FIX--
Recent publications by [Alison Goate[/researchers/[alison-goate[/researchers/[alison-goate[/researchers/[alison-goate--TEMP--/researchers)--FIX-- focus on the genetics of Alzheimer's disease, X-chromosome wide association studies, and pathogenic variants in neurodegenerative diseases.
The study of Alison M. Goate has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Russ et al., Lymphoid gene expression supports neuroprotective microglia function (2025)
Goate et al., Cortical asymmetry in autosomal dominant Alzheimer's Disease progression (2026)
Goate et al., Early microglial priming in Alzheimer's Disease revealed by ME-seq (2026)
Goate A, et al. Genetic architecture of early-onset AD. Nat Genet. 2024;56(11):2133-2145.
Goate A. Pathogenic variants in neurodegenerative disease. Neuron. 2025;113(2):189-203.